Comparative Pharmacology
Head-to-head clinical analysis: OXYTOCIN versus PITOCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXYTOCIN versus PITOCIN.
OXYTOCIN vs PITOCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxytocin is a nonapeptide hormone that binds to oxytocin receptors on the myometrium, stimulating G-protein coupled receptor activation and increasing intracellular calcium, leading to uterine smooth muscle contraction. It also acts on mammary gland myoepithelial cells to induce milk ejection.
Oxytocin receptor agonist; stimulates uterine smooth muscle contractions and myoepithelial cell contraction in the mammary gland.
For induction/augmentation of labor: IV infusion, initial 0.5-2 mU/min, increase by 1-2 mU/min every 30-60 min until desired contraction pattern; max 20 mU/min. For postpartum hemorrhage: IV bolus 3 units (slow push) or IV infusion 10-40 units in 1000 mL crystalloid, rate adjusted to control bleeding; alternatively IM 10 units after delivery of placenta.
IV infusion: 0.5-2 mU/min, increase by 1-2 mU/min every 15-60 minutes until contractions are established; maximum 20 mU/min.
None Documented
None Documented
Terminal elimination half-life: 1–6 minutes (intravenous); clinical context: rapid offset requires continuous infusion for sustained uterine contraction.
Terminal elimination half-life is 3-5 minutes (plasma) with a terminal half-life of 1-6 minutes for exogenously administered oxytocin; clinical effects persist 20-30 minutes due to receptor binding.
Renal: >99% as intact oxytocin and metabolites; biliary/fecal: negligible.
Primarily renal: 90-95% of the dose is excreted in urine as intact peptide and metabolites; <1% excreted in feces via bile.
Category C
Category C
Oxytocic
Oxytocic